HK1117381A1 - Granular preparation containing biguanide compound - Google Patents

Granular preparation containing biguanide compound

Info

Publication number
HK1117381A1
HK1117381A1 HK08107710.6A HK08107710A HK1117381A1 HK 1117381 A1 HK1117381 A1 HK 1117381A1 HK 08107710 A HK08107710 A HK 08107710A HK 1117381 A1 HK1117381 A1 HK 1117381A1
Authority
HK
Hong Kong
Prior art keywords
preparation containing
granular preparation
biguanide compound
containing biguanide
compound
Prior art date
Application number
HK08107710.6A
Other languages
English (en)
Inventor
Yasushi Ochiai
Yasuhiro Matsui
Original Assignee
Dainippon Sumitomo Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Sumitomo Pharma Co filed Critical Dainippon Sumitomo Pharma Co
Publication of HK1117381A1 publication Critical patent/HK1117381A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Glanulating (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
HK08107710.6A 2005-04-26 2008-07-14 Granular preparation containing biguanide compound HK1117381A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005127360 2005-04-26
PCT/JP2006/308711 WO2006118137A1 (ja) 2005-04-26 2006-04-26 ビグアナイド系薬物を含有する粒状製剤

Publications (1)

Publication Number Publication Date
HK1117381A1 true HK1117381A1 (en) 2009-01-16

Family

ID=37307936

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08107710.6A HK1117381A1 (en) 2005-04-26 2008-07-14 Granular preparation containing biguanide compound

Country Status (14)

Country Link
US (1) US8192761B2 (sl)
EP (2) EP1878426B1 (sl)
JP (1) JP5084499B2 (sl)
KR (1) KR20080007371A (sl)
CN (1) CN101198319B (sl)
CA (1) CA2607419C (sl)
CY (1) CY1110756T1 (sl)
DE (1) DE602006014958D1 (sl)
ES (1) ES2343432T3 (sl)
HK (1) HK1117381A1 (sl)
PL (1) PL1878426T3 (sl)
PT (1) PT1878426E (sl)
SI (1) SI1878426T1 (sl)
WO (1) WO2006118137A1 (sl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
KR20090081407A (ko) * 2006-10-25 2009-07-28 다이닛본 스미토모 세이야꾸 가부시끼가이샤 고결 방지 과립상 제제
US20080107787A1 (en) * 2006-11-02 2008-05-08 The Coca-Cola Company Anti-Diabetic Composition with High-Potency Sweetener
US20100034894A1 (en) * 2008-08-08 2010-02-11 Szymczak Christopher E Use of Sucralose as a Granulating Agent
TW201138843A (en) 2009-12-18 2011-11-16 Colgate Palmolive Co Biguanide preservation of precipitated calcium carbonate
WO2011154975A2 (en) 2010-06-08 2011-12-15 Cadila Healthcare Limited Pharmaceutical compositions of metformin
JP5860480B2 (ja) 2011-01-11 2016-02-16 キャプシュゲル・ベルジウム・エヌ・ヴィ プルランを含む新しい硬カプセル
CN110678555B (zh) 2017-04-14 2023-10-13 比利时胶囊公司 制作普鲁兰的方法
US11576870B2 (en) 2017-04-14 2023-02-14 Capsugel Belgium Nv Pullulan capsules
US20200093646A1 (en) * 2018-09-20 2020-03-26 Kci Licensing, Inc. Super-absorbent, low trauma, advanced wound dressing

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JP3583166B2 (ja) 1994-06-27 2004-10-27 興和株式会社 損傷皮膚修復用粉末製剤
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
US6413541B1 (en) * 1999-01-13 2002-07-02 Dainippon Pharmaceutical Co., Ltd. Disintegrating tablet in oral cavity and production thereof
JP4606582B2 (ja) 1998-04-29 2011-01-05 大日本住友製薬株式会社 ビグアナイド系薬物の内服製剤
ATE269069T1 (de) * 1998-04-29 2004-07-15 Sumitomo Pharma Orale zubereitung enthaltend einen biguanid und eine organische säure
AR030920A1 (es) 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
IL154307A0 (en) * 2000-08-07 2003-09-17 Ranbaxy Signature Llc Liquid formulation of metformin
JP2002241267A (ja) * 2000-12-11 2002-08-28 Takeda Chem Ind Ltd 水溶解性が改善された医薬組成物
DE60211769T2 (de) * 2001-03-07 2007-05-24 Dainippon Sumitomo Pharma Co., Ltd. Verfahren zur Herstellung von Arzneistoffgranulatkörnern, die Arzneistoffgranulatkörner sowie diese enthaltende pharmazeutische Zubereitungen
JP4438268B2 (ja) * 2001-03-07 2010-03-24 大日本住友製薬株式会社 薬物顆粒の製造方法、および薬物顆粒、ならびにそれを用いた医薬製剤
CA2461693A1 (en) * 2001-09-28 2003-04-03 Sun Pharmaceutical Industries Limited Dosage form for treatment of diabetes mellitus
WO2003099214A2 (en) 2002-05-23 2003-12-04 Andrx Corporation Biguanide formulations
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
UA80991C2 (en) * 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
CN1805738A (zh) * 2003-06-16 2006-07-19 兰贝克赛实验室有限公司 持续释放的二甲双胍片剂
FR2858556B1 (fr) 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
JP2005068116A (ja) * 2003-08-28 2005-03-17 Toa Eiyo Ltd 塩酸メトホルミンを含有する速放性フィルムコーティング錠剤
JP2005139173A (ja) * 2003-10-17 2005-06-02 Medorekkusu:Kk ビグアナイド系薬剤を含有するゼリー製剤
CA2542755A1 (en) * 2003-10-17 2005-04-28 Medrx Co., Ltd. Biguanide drug-containing jelly preparation
WO2005072717A1 (ja) 2004-01-29 2005-08-11 Dainippon Sumitomo Pharma Co., Ltd. ビグアナイド系薬物の内服製剤

Also Published As

Publication number Publication date
EP2204169A1 (en) 2010-07-07
JP5084499B2 (ja) 2012-11-28
PT1878426E (pt) 2010-06-28
ES2343432T3 (es) 2010-07-30
DE602006014958D1 (de) 2010-07-29
EP1878426A4 (en) 2008-12-24
CY1110756T1 (el) 2015-06-10
SI1878426T1 (sl) 2010-09-30
CA2607419C (en) 2014-06-17
CN101198319A (zh) 2008-06-11
US20090130215A1 (en) 2009-05-21
CN101198319B (zh) 2012-08-01
PL1878426T3 (pl) 2010-11-30
KR20080007371A (ko) 2008-01-18
CA2607419A1 (en) 2006-11-09
US8192761B2 (en) 2012-06-05
WO2006118137A1 (ja) 2006-11-09
EP1878426A1 (en) 2008-01-16
JPWO2006118137A1 (ja) 2008-12-18
EP1878426B1 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
HK1117381A1 (en) Granular preparation containing biguanide compound
GB0510139D0 (en) Novel compounds B1
GB0500492D0 (en) Compound
GB0513702D0 (en) Compound
GB0506133D0 (en) Compound
EP1876179A4 (en) THIENOPYRIMIDONVERBINDUNGEN
GB0520955D0 (en) Compound
EP1961741A4 (en) M-CARBAZOLYLPHENYL COMPOUNDS
GB0502310D0 (en) Compounds
GB0502299D0 (en) Compounds
GB0512429D0 (en) Novel compound
AP2007004220A0 (en) Motilide compounds
GB0525323D0 (en) Compound
EP1907385A4 (en) LINKS
GB0509829D0 (en) Compound
TWI367727B (en) Granular sucralose
GB0616173D0 (en) Compound
GB0501985D0 (en) Compounds
GB0504998D0 (en) Antimicrobial compounds
GB0524685D0 (en) Compound
GB0516378D0 (en) Compound
EP1867650A4 (en) HYDROXYMETHYLBORVERBINDUNGEN
GB0501984D0 (en) Compounds
KZ19273A (en) Compound container
EP1961756A4 (en) NEW BISBORNET CONNECTION

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170426